Recent therapeutic advances in gynecologic oncology: evolving roles of immunotherapy, antibody–drug conjugates, and clinical trial innovations
Immunotherapy and ADCs represent major advances in the treatment of gynecologic cancers. Their growing integration into clinical practice has reshaped therapeutic approaches, while ongoing research continues to refine optimal combinations, address resistance, and enhance biomarker-guided selection. Future developments are expected to unite immunologic, genomic, and computational strategies to achieve personalized and durable outcomes for patients with gynecologic malignancies.
Authors
- Akerke Amirkhanova (ORCID: https://orcid.org/0000-0003-1479-3171)
- Arailym Abilbayeva (ORCID: https://orcid.org/0000-0001-5081-5492)
- Aida Seitaliyeva (ORCID: https://orcid.org/0000-0003-0177-5599)
- Altyn Abilova
- Zhanserik Shynykul (ORCID: https://orcid.org/0000-0002-2551-0723)
- Akmaral Maimakova
- Alma Nurakhova
- Z. Dushimova (ORCID: https://orcid.org/0000-0003-0791-4246)
- Sholpan Akhelova (ORCID: https://orcid.org/0000-0001-6539-2752)
- AIKEN ORAZYMBETOVA
- Nurgulim Akhmad
- Sandugash Yerkenova
- Gaukhar Koshkimbayeva
- Dana Akhmentayeva (ORCID: https://orcid.org/0000-0001-9395-8397)
- Altyn Duisenbayeva
Institutions
- Al-Farabi Kazakh National University (KZ)
- Kazakh National Medical University (KZ)
- University of International Business (KZ)
- Kazakhstan Medical University (KZ)
- Astana Medical University (KZ)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-15
- DOI
- https://doi.org/10.3389/fonc.2025.1697180
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00